ENTA (Enanta Pharmaceuticals) Cyclically Adjusted Book per Share: $18.40 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENTA Enanta Pharmaceuticals Inc ENTA
49 GF Score
Price $13.95
GF Value $7.93
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Cyclically Adjusted Book per Share?

Enanta Pharmaceuticals ENTA -0.92% 49 Cyclically Adjusted Book per Share is $18.40 as of Jun. 2026. GuruFocus rates ENTA with a GF Score™ of 49/100 and a GF Value™ of $7.93 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Enanta Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2026 was $3.471. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $18.40 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Enanta Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -4.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Enanta Pharmaceuticals was 8.00% per year. The lowest was 1.50% per year. And the median was 4.75% per year.

As of today (2026-08-26), Enanta Pharmaceuticals's current stock price is $13.95. Enanta Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $18.40. Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.76.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enanta Pharmaceuticals was 6.25. The lowest was 0.24. And the median was 0.75.


Enanta Pharmaceuticals  (NAS:ENTA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=13.95/18.40
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enanta Pharmaceuticals was 6.25. The lowest was 0.24. And the median was 0.75.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Enanta Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Enanta Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Cyclically Adjusted Book per Share Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.59 18.20 19.35 19.66 19.05

Enanta Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.27 19.05 18.63 18.60 18.40

ENTA vs CMPX, CCCC, LXEO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


ENTA
49GF Score
Enanta Pharmaceuticals Inc ENTA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enanta Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.471/333.9520*333.9520
=3.471

Current CPI (Jun. 2026) = 333.9520.

Enanta Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 14.180 241.428 19.614
201612 14.084 241.432 19.481
201703 13.961 243.801 19.123
201706 13.665 244.955 18.630
201709 15.778 246.819 21.348
201712 16.584 246.524 22.465
201803 17.311 249.554 23.165
201806 18.642 251.989 24.706
201809 20.298 252.439 26.852
201812 21.962 251.233 29.193
201903 22.178 254.202 29.136
201906 22.767 256.143 29.683
201909 23.473 256.759 30.530
201912 24.346 256.974 31.639
202003 24.317 258.115 31.462
202006 23.944 257.797 31.017
202009 22.692 260.280 29.115
202012 22.440 260.474 28.770
202103 21.602 264.877 27.235
202106 20.674 271.696 25.411
202109 19.737 274.310 24.028
202112 18.745 278.802 22.453
202203 17.392 287.504 20.202
202206 16.313 296.311 18.385
202209 15.455 296.808 17.389
202212 14.405 296.797 16.208
202303 12.798 301.836 14.160
202306 11.295 305.109 12.363
202309 10.292 307.789 11.167
202312 9.070 306.746 9.874
202403 7.843 312.332 8.386
202406 7.030 314.175 7.473
202409 6.078 315.301 6.438
202412 5.241 315.605 5.546
202503 4.376 319.799 4.570
202506 3.708 322.561 3.839
202509 3.026 324.800 3.111
202512 4.362 324.054 4.495
202603 4.012 330.213 4.057
202606 3.471 333.952 3.471

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $18.40 mean?
Enanta Pharmaceuticals (ENTA) has a Cyclically Adjusted Book per Share of $18.40 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Enanta Pharmaceuticals' current Cyclically Adjusted Book per Share is $18.40. Overall, Enanta Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Cyclically Adjusted Book per Share compare to CMPX and CCCC?
Enanta Pharmaceuticals' Cyclically Adjusted Book per Share of $18.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current Cyclically Adjusted Book per Share is $18.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (ENTA) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.93, compared to a current price of $13.95 — trading 75.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is $18.40. Enanta Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Enanta Pharmaceuticals (ENTA), the current Cyclically Adjusted Book per Share is $18.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (ENTA) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of $13.95 is trading 75.9% above its estimated GF Value™ of $7.93. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ENTA:

  • Cyclically Adjusted Book per Share: $18.40
  • GF Value™: $7.93 vs. price of $13.95 (75.9% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ENTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enanta Pharmaceuticals Business Description

Other Exchanges 9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
49GF Score

Get the complete analysis for ENTA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.95
Price
$7.93
GF Value